<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01774357</url>
  </required_header>
  <id_info>
    <org_study_id>TA102</org_study_id>
    <nct_id>NCT01774357</nct_id>
  </id_info>
  <brief_title>Management and Detection of Atrial Tachyarrhythmias in Patients Implanted With BIOTRONIK DX Systems</brief_title>
  <acronym>MATRIX</acronym>
  <official_title>Management and Detection of Atrial Tachyarrhythmias in Patients Implanted With BIOTRONIK DX Systems</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biotronik SE &amp; Co. KG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biotronik SE &amp; Co. KG</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an observational registry study aiming to collect data on efficacy and safety of the&#xD;
      single chamber Biotronik DX system with enhanced atrial diagnostics. The minimal follow-up&#xD;
      period is 24 months. All analyses on the data will be done post-hoc; the study does not&#xD;
      intend to confirm any pre-specified hypotheses.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Enrollment (E0)&#xD;
&#xD;
      Timing:&#xD;
&#xD;
      • The enrollment (date of patient written informed consent) starts after implantation of a&#xD;
      BIOTRONIK Lumax 540 VR-T DX ICD with Linoxsmart S DX or successor single chamber DX system&#xD;
      according to current guidelines (primary or secondary prevention) but should not be later&#xD;
      than 90 days after implantation.&#xD;
&#xD;
      Procedures:&#xD;
&#xD;
        -  Check inclusion and exclusion criteria&#xD;
&#xD;
        -  Patient information and written informed consent process&#xD;
&#xD;
        -  Assignment of a unique study code&#xD;
&#xD;
        -  ICD interrogation (re-programming if necessary)&#xD;
&#xD;
        -  HMSC registration (recommended)&#xD;
&#xD;
        -  Investigator assessment: appropriate atrial sensing&#xD;
&#xD;
      Documentation (note: where available the most recent assessment recorded within six months&#xD;
      prior to hospital discharge shall be considered):&#xD;
&#xD;
        -  Medical History:&#xD;
&#xD;
             -  Demographic data&#xD;
&#xD;
             -  General history of cardiovascular disease&#xD;
&#xD;
             -  Etiology of underlying heart disease&#xD;
&#xD;
             -  Cardiac events and symptoms&#xD;
&#xD;
             -  Documented supraventricular arrhythmia prior to implantation&#xD;
&#xD;
        -  Device Interrogation&#xD;
&#xD;
             -  Date, home monitoring function, MRI scan&#xD;
&#xD;
        -  AF history:&#xD;
&#xD;
             -  type (none, paroxysmal, persistent, permanent)&#xD;
&#xD;
             -  date of first diagnosis (if applicable)&#xD;
&#xD;
             -  EHRA classification (if applicable)&#xD;
&#xD;
             -  AF burden (if available)&#xD;
&#xD;
             -  CHA2DS2-VASc&#xD;
&#xD;
             -  Risk factors and comorbidities:&#xD;
&#xD;
             -  thyroid dysfunction&#xD;
&#xD;
             -  diabetes mellitus&#xD;
&#xD;
             -  COPD&#xD;
&#xD;
             -  sleep apnea&#xD;
&#xD;
             -  chronic renal disease&#xD;
&#xD;
             -  History of thromboembolic events or stroke&#xD;
&#xD;
        -  Physical Examination:&#xD;
&#xD;
             -  Vital signs (SBP, DBP, height, body weight, BMI)&#xD;
&#xD;
             -  Current medication (substance class)&#xD;
&#xD;
             -  Heart failure indices&#xD;
&#xD;
             -  NYHA classification&#xD;
&#xD;
             -  BNP and NT-proBNP (only if determined in routine clinical practice)&#xD;
&#xD;
             -  LVEF (optional; echocardiography preferred, other methods accepted if no echo&#xD;
                available)&#xD;
&#xD;
             -  ECG parameters (12 lead ECG; optional)&#xD;
&#xD;
             -  RR, PQ, and QT intervals&#xD;
&#xD;
             -  QRS width&#xD;
&#xD;
             -  rhythm disorders&#xD;
&#xD;
             -  clinical findings, morphology&#xD;
&#xD;
        -  Implantation:&#xD;
&#xD;
             -  Indication (primary prevention, secondary prevention)&#xD;
&#xD;
             -  Type of procedure (first implantation / replacement)&#xD;
&#xD;
             -  RV lead:&#xD;
&#xD;
             -  Dislodgement / repositioning after implantation?&#xD;
&#xD;
             -  Sufficient amplitudes (Atrial; Ventricular) and thresholds (Ventricular)&#xD;
&#xD;
             -  Other clinical complications during / after implantation?&#xD;
&#xD;
             -  Final lead position at discharge (apical, septal, other)&#xD;
&#xD;
             -  Atrial dipole (with or without atrial wall contact at rest)&#xD;
&#xD;
             -  Ease of implantation as assessed by investigator&#xD;
&#xD;
             -  An extended questionnaire including more detailed information on implantation&#xD;
                procedure, technique and initial measurements will be requested as an optional&#xD;
                documentation where data are available&#xD;
&#xD;
      Follow-up Y1 and Y2&#xD;
&#xD;
      Timing:&#xD;
&#xD;
      • 12 and 24 months (+/-2 months) after enrollment respectively&#xD;
&#xD;
      Procedures:&#xD;
&#xD;
        -  ICD interrogation / function check-up and re-programming if necessary&#xD;
&#xD;
        -  Programmer download of all data not yet submitted to BIOTRONIK according to current&#xD;
           working instruction&#xD;
&#xD;
        -  Investigator assessment: appropriate atrial sensing&#xD;
&#xD;
      Documentation (note: where available the most recent assessment recorded between the current&#xD;
      and the preceding visit shall be considered):&#xD;
&#xD;
        -  Physical Examination:&#xD;
&#xD;
             -  Vital signs (SBP, DBP, height, body weight, BMI)&#xD;
&#xD;
             -  Current medication (substance class)&#xD;
&#xD;
             -  Heart Failure indices:&#xD;
&#xD;
             -  NYHA classification&#xD;
&#xD;
             -  BNP and NT-proBNP (only if determined in routine clinical practice)&#xD;
&#xD;
             -  LVEF (optional; echocardiography preferred, other methods accepted if no echo&#xD;
                available)&#xD;
&#xD;
             -  ECG parameters (12 lead ECG; optional):&#xD;
&#xD;
             -  RR, PQ, and QT intervals&#xD;
&#xD;
             -  QRS width&#xD;
&#xD;
             -  rhythm disorders&#xD;
&#xD;
             -  clinical findings, morphology&#xD;
&#xD;
        -  Device Interrogation&#xD;
&#xD;
             -  Date, home monitoring function, MRI scan&#xD;
&#xD;
      Event based documentation&#xD;
&#xD;
        -  New-onset or worsening AF&#xD;
&#xD;
        -  AF interventions&#xD;
&#xD;
        -  Worsening heart failure&#xD;
&#xD;
        -  Shock episode&#xD;
&#xD;
        -  Thromboembolic events (CVA, TIA, PAE)&#xD;
&#xD;
        -  Continuous surveillance / reporting of (serious) adverse events / (serious) adverse&#xD;
           device effects&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Actual">September 19, 2018</completion_date>
  <primary_completion_date type="Actual">September 2018</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>2 Years</target_duration>
  <primary_outcome>
    <measure>Frequency and types of AF-related complications</measure>
    <time_frame>24 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to occurrence of first AF-related complication</measure>
    <time_frame>24 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to AF-related intervention after detection of de novo or worsening AF</measure>
    <time_frame>24 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Frequency and type of complications related to implantation</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency and type of lead-related complications</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular hospitalization with days in hospital</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Significance of AF in acute decompensation of heart failure</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Interventions based on Home Monitoring information regarding AF</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">2054</enrollment>
  <condition>Atrial Fibrillation</condition>
  <condition>Tachycardia</condition>
  <condition>ICD Therapy</condition>
  <condition>Thromboembolic Events</condition>
  <condition>Heart Failure</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with an indication for implantation of a single chamber ICD (primary or secondary&#xD;
        prevention) according to current guidelines and after implantation of a BIOTRONIK Lumax 540&#xD;
        VR-T DX ICD with Linoxsmart S DX or successor single chamber DX system within 90 days prior&#xD;
        to enrollment&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Indication for implantation of a single chamber ICD (primary or secondary prevention)&#xD;
             according to current guidelines&#xD;
&#xD;
          -  Implanted with a BIOTRONIK Lumax 540 VR-T DX ICD with Linoxsmart S DX or successor&#xD;
             single chamber DX system within 90 days prior to enrollment&#xD;
&#xD;
          -  Written informed consent, willingness and ability to comply with the protocol&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age &lt; 18 years&#xD;
&#xD;
          -  Any limitation to contractual capability&#xD;
&#xD;
          -  Female patients who are pregnant or breast feeding or plan a pregnancy during the&#xD;
             course of the study&#xD;
&#xD;
          -  Known active malignant disease or recovered from malignant disease within 2 years&#xD;
             prior to enrollment&#xD;
&#xD;
          -  Simultaneous participation in another study&#xD;
&#xD;
          -  Life expectancy &lt; 2 years&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gerhard Hindricks, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Herzzentrum Leipzig, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Herzzentrum Leipzig</name>
      <address>
        <city>Leipzig</city>
        <state>Sachsen</state>
        <zip>04289</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>September 2018</verification_date>
  <study_first_submitted>January 21, 2013</study_first_submitted>
  <study_first_submitted_qc>January 23, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 24, 2013</study_first_posted>
  <last_update_submitted>September 24, 2018</last_update_submitted>
  <last_update_submitted_qc>September 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">September 25, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
    <mesh_term>Tachycardia</mesh_term>
    <mesh_term>Thromboembolism</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

